| Literature DB >> 27089513 |
Hanane Laklai1, Yekaterina A Miroshnikova1, Michael W Pickup1, Eric A Collisson2, Grace E Kim3, Alex S Barrett4, Ryan C Hill4, Johnathon N Lakins1, David D Schlaepfer5, Janna K Mouw1, Valerie S LeBleu6, Nilotpal Roy7, Sergey V Novitskiy8, Julia S Johansen9, Valeria Poli10, Raghu Kalluri6, Christine A Iacobuzio-Donahue11, Laura D Wood12, Matthias Hebrok7, Kirk Hansen4, Harold L Moses8, Valerie M Weaver1,13,14,15,16.
Abstract
Fibrosis compromises pancreatic ductal carcinoma (PDAC) treatment and contributes to patient mortality, yet antistromal therapies are controversial. We found that human PDACs with impaired epithelial transforming growth factor-β (TGF-β) signaling have high epithelial STAT3 activity and develop stiff, matricellular-enriched fibrosis associated with high epithelial tension and shorter patient survival. In several KRAS-driven mouse models, both the loss of TGF-β signaling and elevated β1-integrin mechanosignaling engaged a positive feedback loop whereby STAT3 signaling promotes tumor progression by increasing matricellular fibrosis and tissue tension. In contrast, epithelial STAT3 ablation attenuated tumor progression by reducing the stromal stiffening and epithelial contractility induced by loss of TGF-β signaling. In PDAC patient biopsies, higher matricellular protein and activated STAT3 were associated with SMAD4 mutation and shorter survival. The findings implicate epithelial tension and matricellular fibrosis in the aggressiveness of SMAD4 mutant pancreatic tumors and highlight STAT3 and mechanics as key drivers of this phenotype.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27089513 PMCID: PMC4860133 DOI: 10.1038/nm.4082
Source DB: PubMed Journal: Nat Med ISSN: 1078-8956 Impact factor: 53.440